Interactions between the regulatory peptide 26RFa (QRFP) and insulin in the regulation of glucose homeostasis in two complementary models: The high fat 26RFa-deficient mice and the streptozotocin insulin-deficient mice

Archive ouverte

Le Solliec, Marie-Anne | Arabo, Arnaud | Takhlidjt, Saloua | Maucotel, Julie | Devère, Mélodie | Berrahmoune, Hind | Benani, Alexandre | Nedelec, Emmanuelle | Lefranc, Benjamin | Leprince, Jérôme | Picot, Marie | Chartrel, Nicolas | Prévost, Gaëtan

Edité par CCSD ; Elsevier -

International audience. The regulatory peptide 26RFa (QRFP) is involved in the control of glucose homeostasis at the periphery by acting as an incretin, and in the brain by mediating the central antihyperglycemic effect of insulin, indicating the occurrence of a close relationship between 26RFa and insulin in the regulation of glucose metabolism. Here, we investigated the physiological interactions between 26RFa and insulin in two complementary models i.e. a model of obese/hyperglycemic mice deficient for 26RFa and a model of diabetic mice deficient for insulin. For this, transgenic 26RFa-deficient mice were made obese and chronically hyperglycemic by a 3-month high fat diet (HFD) and second group of mice was made diabetic by destruction of the β cells of the pancreatic islets using a single injection of streptozotocin. Our data reveal that 26RFa deficiency does not impact significantly the “glycemic” phenotype of the HFD mice. The pancreatic islets, liver, white adipose tissue masses are not altered by the lack of 26RFa production but the brown adipose tissue (BAT) weight is significantly increased in these an- imals. In diabetic insulin-deficient mice, the injection of 26RFa does not exhibit any beneficial effect on the impaired glucose homeostasis characterizing this model. Finally, we show that streptozotocin diabetic mice display lowered plasma 26RFa levels as compared to untreated mice, whereas the expression of the peptide in the duodenum is not affected. Taken together, the present results indicate that dysregulation of glucose homeostasis in obese/hyperglycemic mice is not aggravated by the absence of 26RFa that may be compensated by the increase of BAT mass. In diabetic insulin-deficient mice, the antihypergycemic effect of 26RFa is totally blunted probably as a result of the impaired insulin production characterizing this model, avoiding therefore the action of the peptide.

Suggestions

Du même auteur

Role of 26RFa/GPR103 system in the regulation of glycemia in a mouse model of obesity and chronic hyperglycemia. Role du système neuropeptidergique 26RFa/GPR103 dans la régulation de la glycémie dans un modèle murin d'obésité et d'hyperglycémie chronique.

Archive ouverte | Le Solliec, Marie-Anne | CCSD

Recent studies revealed that the neuropeptide 26RFa and its receptor, GPR103, are involved in the regulation of glucose homeostasis. Indeed, it was shown that 26RFa exerts an incretin effect. 26RFa is mainly secreted by the duoden...

Acute but Not Chronic Central Administration of the Neuropeptide 26RFa (QRFP) Improves Glucose Homeostasis in Obese/Diabetic Mice

Archive ouverte | Le Solliec, Marie-Anne | CCSD

International audience. Introduction: The aim of the study is to investigate whether acute or chronic central administration of the hypothalamic neuropeptide 26RFa may ameliorate the glycemic control of obese/diabet...

The 26RFa (QRFP)/GPR103 neuropeptidergic system in mice relays insulin signalling into the brain to regulate glucose homeostasis

Archive ouverte | El Mehdi, Mouna | CCSD

International audience. AIMS/HYPOTHESIS: 26RFa (pyroglutamilated RFamide peptide [QRFP]) is a biologically active peptide that regulates glucose homeostasis by acting as an incretin and by increasing insulin sensiti...

Chargement des enrichissements...